KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Profit After Tax (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Profit After Tax for 8 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 124.32% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Dec 2025, down 232.41% year-over-year, with the annual reading at -$24.2 million for FY2025, 232.41% down from the prior year.
  • Profit After Tax hit -$2.3 million in Q4 2025 for Castle Biosciences, down from -$501000.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $9.6 million in Q4 2024 to a low of -$29.2 million in Q1 2023.
  • Historically, Profit After Tax has averaged -$8.1 million across 5 years, with a median of -$5.4 million in 2021.
  • Biggest five-year swings in Profit After Tax: tumbled 1039.38% in 2023 and later surged 471.71% in 2024.
  • Year by year, Profit After Tax stood at -$6.4 million in 2021, then crashed by 220.65% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then tumbled by 124.32% to -$2.3 million in 2025.
  • Business Quant data shows Profit After Tax for CSTL at -$2.3 million in Q4 2025, -$501000.0 in Q3 2025, and $4.5 million in Q2 2025.